Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Arnold J. Weil, Elizabeth T. Masters, Alexandra I. Barsdorf, Almasa Bass, Glenn Pixton, Jacquelyn G. Wilson, Gernot Wolfram

ABSTRACT

BACKGROUND: The efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone, in the treatment of chronic low back pain (CLBP) was studied in a 12-week randomized controlled trial. Primary efficacy endpoint results have been published previously (Rauck et al., 2015). The current paper focuses on patient-reported outcomes for health-related quality of life (HRQL), work productivity, and activity impairment that were assessed during this study. METHODS: This was a double-blind, placebo-controlled, randomized withdrawal study in patients with moderate-to-severe CLBP. After a screening period (≤2 weeks), patients entered an open-label titration period (4-6 weeks). Treatment responders were then randomized to a double-blind placebo-controlled treatment period (12 weeks). HRQL was assessed using changes in the Short Form-36 v2 Health Survey (SF-36v2) and the EuroQol-5 Dimensions Health Questionnaire 3-Level version (EQ-5D-3L). Work productivity and regular activities were evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP). RESULTS: A total of 410 patients received ALO-02 during the open-label titration period, of which 280 (intent-to-treat (ITT) population) were treated during the double-blind placebo-controlled treatment period (placebo, n = 134; ALO-02, n = 146). Significant improvement was observed for all SF-36v2 subscales and component scores (p < 0.005) and the EQ-5D-3L summary index and visual analog scale (p < 0.0001) during the titration period. Improvement was also significant (p < 0.0001) for all WPAI:SHP outcomes except 'work time missed due to CLBP' for the titration period. Significant differences favoring ALO-02 compared with placebo were only observed for the SF-36v2 Bodily Pain subscale (p ≤ 0.0232; ITT population) during the double-blind treatment period and the overall study period (screening to the end of the double-blind treatment period). The percentage change in activity impairment due to low back pain subscale of the WPAI:SHP significantly favored ALO-02 compared with placebo for the ITT population when considering the overall study period (p = 0.0040). CONCLUSIONS: HRQL, work productivity, and activity impairment may be improved with ALO-02 treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT01571362 , registered April 3, 2012. More... »

PAGES

202

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12955-017-0749-y

DOI

http://dx.doi.org/10.1186/s12955-017-0749-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092249050

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29041942


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Analgesics, Opioid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Delayed-Action Preparations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Efficiency", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Low Back Pain", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Naltrexone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxycodone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pain Measurement", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Reported Outcome Measures", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Visual Analog Scale", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Non-Surgical Orthopaedics (United States)", 
          "id": "https://www.grid.ac/institutes/grid.488790.a", 
          "name": [
            "Non-Surgical Orthopaedics, PC, 335 Roselane St NW, 30067, Marietta, GA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weil", 
        "givenName": "Arnold J.", 
        "id": "sg:person.01230314714.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230314714.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, 235 E 42nd St, 10017, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masters", 
        "givenName": "Elizabeth T.", 
        "id": "sg:person.01210415200.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210415200.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, 235 E 42nd St, 10017, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barsdorf", 
        "givenName": "Alexandra I.", 
        "id": "sg:person.01105124405.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105124405.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pfizer Inc, 4222 Emperor Boulevard, Suite 335, 27703, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bass", 
        "givenName": "Almasa", 
        "id": "sg:person.01023710211.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023710211.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pfizer Inc, 4222 Emperor Boulevard, Suite 335, 27703, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pixton", 
        "givenName": "Glenn", 
        "id": "sg:person.01140136611.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140136611.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pfizer Inc, 4222 Emperor Boulevard, Suite 335, 27703, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilson", 
        "givenName": "Jacquelyn G.", 
        "id": "sg:person.01052152607.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052152607.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pfizer Inc, 4222 Emperor Boulevard, Suite 335, 27703, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolfram", 
        "givenName": "Gernot", 
        "id": "sg:person.01342340211.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342340211.86"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/jama.2016.1464", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011046696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2016.1464", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011046696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2016.1464", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011046696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jpain.2015.05.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015865413"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jpain.2008.10.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017591588"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ajp.0b013e3181b12dec", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020523539"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ajp.0b013e3181b12dec", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020523539"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ajp.0b013e3181b12dec", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020523539"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ajp.0b013e3181b12dec", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020523539"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0168-8510(96)00822-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023757917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/j.pain.0000000000000230", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024509155"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/j.pain.0000000000000230", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024509155"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199304050-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027738237", 
          "https://doi.org/10.2165/00019053-199304050-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.amjmed.2012.11.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028595156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0168-8510(90)90421-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033898358"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14656566.2010.491510", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037268596"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1524-4733.2003.65309.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041198010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1524-4733.2003.65309.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041198010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.spinee.2007.11.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041594967"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pain.2012.03.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043275234"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pain.2012.03.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043275234"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-014-0099-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046255156", 
          "https://doi.org/10.1007/s12325-014-0099-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11136-004-7713-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050041047", 
          "https://doi.org/10.1007/s11136-004-7713-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11136-004-7713-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050041047", 
          "https://doi.org/10.1007/s11136-004-7713-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11136-004-7713-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050041047", 
          "https://doi.org/10.1007/s11136-004-7713-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.15585/mmwr.mm655051e1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067984551"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "BACKGROUND: The efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone, in the treatment of chronic low back pain (CLBP) was studied in a 12-week randomized controlled trial. Primary efficacy endpoint results have been published previously (Rauck et al., 2015). The current paper focuses on patient-reported outcomes for health-related quality of life (HRQL), work productivity, and activity impairment that were assessed during this study.\nMETHODS: This was a double-blind, placebo-controlled, randomized withdrawal study in patients with moderate-to-severe CLBP. After a screening period (\u22642 weeks), patients entered an open-label titration period (4-6 weeks). Treatment responders were then randomized to a double-blind placebo-controlled treatment period (12 weeks). HRQL was assessed using changes in the Short Form-36 v2 Health Survey (SF-36v2) and the EuroQol-5 Dimensions Health Questionnaire 3-Level version (EQ-5D-3L). Work productivity and regular activities were evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP).\nRESULTS: A total of 410 patients received ALO-02 during the open-label titration period, of which 280 (intent-to-treat (ITT) population) were treated during the double-blind placebo-controlled treatment period (placebo, n = 134; ALO-02, n = 146). Significant improvement was observed for all SF-36v2 subscales and component scores (p < 0.005) and the EQ-5D-3L summary index and visual analog scale (p < 0.0001) during the titration period. Improvement was also significant (p < 0.0001) for all WPAI:SHP outcomes except 'work time missed due to CLBP' for the titration period. Significant differences favoring ALO-02 compared with placebo were only observed for the SF-36v2 Bodily Pain subscale (p \u2264 0.0232; ITT population) during the double-blind treatment period and the overall study period (screening to the end of the double-blind treatment period). The percentage change in activity impairment due to low back pain subscale of the WPAI:SHP significantly favored ALO-02 compared with placebo for the ITT population when considering the overall study period (p = 0.0040).\nCONCLUSIONS: HRQL, work productivity, and activity impairment may be improved with ALO-02 treatment.\nTRIAL REGISTRATION: ClinicalTrials.gov NCT01571362 , registered April 3, 2012.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12955-017-0749-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031326", 
        "issn": [
          "1477-7525"
        ], 
        "name": "Health and Quality of Life Outcomes", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain", 
    "pagination": "202", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "ed3c00e852f74fc33291bb2f69411656488aefabbf675cffa4b615cd31c4bda5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29041942"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101153626"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12955-017-0749-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092249050"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12955-017-0749-y", 
      "https://app.dimensions.ai/details/publication/pub.1092249050"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000563.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12955-017-0749-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12955-017-0749-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12955-017-0749-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12955-017-0749-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12955-017-0749-y'


 

This table displays all metadata directly associated to this object as RDF triples.

248 TRIPLES      21 PREDICATES      64 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12955-017-0749-y schema:about N0d1adf3f841142698cc86c6c5870cfe4
2 N28c9924e74b249d8b5736b800419cbdc
3 N2ee81fa4b0024605bbc7ac048ff6c6a7
4 N4475bffc29704491a99888b91607d187
5 N4a0bfe1e3e89423aa6ab3ea7cfaf9128
6 N552528466e6c49a2a1e78e0a43e490e0
7 N5674baa042894a00a9a517eec00cf7f0
8 N9aaf595534eb47f5bdbc9710bd3fa4cb
9 Na54daa5cdbfb47bcb33a2559dafd3fd5
10 Naba7109830494de8bf1e2b347e1b729b
11 Nad33a0e3bfda4e75a8277f5b737a036a
12 Nb1ce8de963ef430d93a9ff4e47cb7619
13 Nb8dc420287a446d3b0a6d13fa0ba3cd7
14 Nc0e479021e884f87a28b86f4b669dfa4
15 Nc57718add948441e9a84465ba657e1eb
16 Nd168d2ac0bde4f888bf66275bff6d824
17 Nfcefb982c813478781a17869ae8c2f70
18 Nfd1dcdef68c14313bf0bfb459bff78bc
19 Nfe544422f6ec4bdab6696e7279784452
20 anzsrc-for:11
21 anzsrc-for:1117
22 schema:author Nd95d07362b394bc3b91d0e2bddf67804
23 schema:citation sg:pub.10.1007/s11136-004-7713-0
24 sg:pub.10.1007/s12325-014-0099-7
25 sg:pub.10.2165/00019053-199304050-00006
26 https://doi.org/10.1001/jama.2016.1464
27 https://doi.org/10.1016/0168-8510(90)90421-9
28 https://doi.org/10.1016/0168-8510(96)00822-6
29 https://doi.org/10.1016/j.amjmed.2012.11.011
30 https://doi.org/10.1016/j.jpain.2008.10.008
31 https://doi.org/10.1016/j.jpain.2015.05.002
32 https://doi.org/10.1016/j.pain.2012.03.003
33 https://doi.org/10.1016/j.spinee.2007.11.006
34 https://doi.org/10.1046/j.1524-4733.2003.65309.x
35 https://doi.org/10.1097/ajp.0b013e3181b12dec
36 https://doi.org/10.1097/j.pain.0000000000000230
37 https://doi.org/10.1517/14656566.2010.491510
38 https://doi.org/10.15585/mmwr.mm655051e1
39 schema:datePublished 2017-12
40 schema:datePublishedReg 2017-12-01
41 schema:description BACKGROUND: The efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone, in the treatment of chronic low back pain (CLBP) was studied in a 12-week randomized controlled trial. Primary efficacy endpoint results have been published previously (Rauck et al., 2015). The current paper focuses on patient-reported outcomes for health-related quality of life (HRQL), work productivity, and activity impairment that were assessed during this study. METHODS: This was a double-blind, placebo-controlled, randomized withdrawal study in patients with moderate-to-severe CLBP. After a screening period (≤2 weeks), patients entered an open-label titration period (4-6 weeks). Treatment responders were then randomized to a double-blind placebo-controlled treatment period (12 weeks). HRQL was assessed using changes in the Short Form-36 v2 Health Survey (SF-36v2) and the EuroQol-5 Dimensions Health Questionnaire 3-Level version (EQ-5D-3L). Work productivity and regular activities were evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP). RESULTS: A total of 410 patients received ALO-02 during the open-label titration period, of which 280 (intent-to-treat (ITT) population) were treated during the double-blind placebo-controlled treatment period (placebo, n = 134; ALO-02, n = 146). Significant improvement was observed for all SF-36v2 subscales and component scores (p < 0.005) and the EQ-5D-3L summary index and visual analog scale (p < 0.0001) during the titration period. Improvement was also significant (p < 0.0001) for all WPAI:SHP outcomes except 'work time missed due to CLBP' for the titration period. Significant differences favoring ALO-02 compared with placebo were only observed for the SF-36v2 Bodily Pain subscale (p ≤ 0.0232; ITT population) during the double-blind treatment period and the overall study period (screening to the end of the double-blind treatment period). The percentage change in activity impairment due to low back pain subscale of the WPAI:SHP significantly favored ALO-02 compared with placebo for the ITT population when considering the overall study period (p = 0.0040). CONCLUSIONS: HRQL, work productivity, and activity impairment may be improved with ALO-02 treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT01571362 , registered April 3, 2012.
42 schema:genre research_article
43 schema:inLanguage en
44 schema:isAccessibleForFree true
45 schema:isPartOf N45d2cd0fb31f4e1da855a83eb5526dd8
46 N55d72afa7b78457cb731e4c5b13ae460
47 sg:journal.1031326
48 schema:name Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain
49 schema:pagination 202
50 schema:productId N09370c80a5db466d8f316f40e8195aee
51 N4210cb63214246e58d6fa688b08e0e8a
52 N431b69230ef84465b33968e70318bd62
53 N7b123206dfe94622a4c7f62fafccf3ab
54 Nf13b1f8d16a142eea15dfad9fab7c807
55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092249050
56 https://doi.org/10.1186/s12955-017-0749-y
57 schema:sdDatePublished 2019-04-10T16:50
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher Nf7453204a42b461da2c907369244ed67
60 schema:url https://link.springer.com/10.1186%2Fs12955-017-0749-y
61 sgo:license sg:explorer/license/
62 sgo:sdDataset articles
63 rdf:type schema:ScholarlyArticle
64 N09370c80a5db466d8f316f40e8195aee schema:name doi
65 schema:value 10.1186/s12955-017-0749-y
66 rdf:type schema:PropertyValue
67 N0d1adf3f841142698cc86c6c5870cfe4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Naltrexone
69 rdf:type schema:DefinedTerm
70 N19f65d7fbc8e477aacacdea9f7d387d4 rdf:first sg:person.01052152607.19
71 rdf:rest N8019b9c1225d495b8d882b2a63e26c18
72 N28c9924e74b249d8b5736b800419cbdc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Delayed-Action Preparations
74 rdf:type schema:DefinedTerm
75 N2ee81fa4b0024605bbc7ac048ff6c6a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Low Back Pain
77 rdf:type schema:DefinedTerm
78 N4210cb63214246e58d6fa688b08e0e8a schema:name pubmed_id
79 schema:value 29041942
80 rdf:type schema:PropertyValue
81 N431b69230ef84465b33968e70318bd62 schema:name dimensions_id
82 schema:value pub.1092249050
83 rdf:type schema:PropertyValue
84 N4475bffc29704491a99888b91607d187 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Male
86 rdf:type schema:DefinedTerm
87 N45d2cd0fb31f4e1da855a83eb5526dd8 schema:issueNumber 1
88 rdf:type schema:PublicationIssue
89 N4784861bc1c044f1b043f6bc53f1fb85 schema:name Pfizer Inc, 4222 Emperor Boulevard, Suite 335, 27703, Durham, NC, USA
90 rdf:type schema:Organization
91 N4a0bfe1e3e89423aa6ab3ea7cfaf9128 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Treatment Outcome
93 rdf:type schema:DefinedTerm
94 N4e3d7891f272492b8b10741e4c112ca0 rdf:first sg:person.01105124405.55
95 rdf:rest Ndd46d161e47e4dc486248a6a46618095
96 N552528466e6c49a2a1e78e0a43e490e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Visual Analog Scale
98 rdf:type schema:DefinedTerm
99 N55d72afa7b78457cb731e4c5b13ae460 schema:volumeNumber 15
100 rdf:type schema:PublicationVolume
101 N5674baa042894a00a9a517eec00cf7f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Pain Measurement
103 rdf:type schema:DefinedTerm
104 N5b73de9a74554c7e89afa3332fd066c9 schema:name Pfizer Inc, 4222 Emperor Boulevard, Suite 335, 27703, Durham, NC, USA
105 rdf:type schema:Organization
106 N64c0302e2f1c4407b8bc38a6513371d2 schema:name Pfizer Inc, 4222 Emperor Boulevard, Suite 335, 27703, Durham, NC, USA
107 rdf:type schema:Organization
108 N7b123206dfe94622a4c7f62fafccf3ab schema:name readcube_id
109 schema:value ed3c00e852f74fc33291bb2f69411656488aefabbf675cffa4b615cd31c4bda5
110 rdf:type schema:PropertyValue
111 N8019b9c1225d495b8d882b2a63e26c18 rdf:first sg:person.01342340211.86
112 rdf:rest rdf:nil
113 N87319c496f4b40dbb486c32cbb38b0d9 rdf:first sg:person.01210415200.45
114 rdf:rest N4e3d7891f272492b8b10741e4c112ca0
115 N8cd634bc3bfb4137af1bd7869ac3ee92 schema:name Pfizer Inc, 4222 Emperor Boulevard, Suite 335, 27703, Durham, NC, USA
116 rdf:type schema:Organization
117 N9aaf595534eb47f5bdbc9710bd3fa4cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Surveys and Questionnaires
119 rdf:type schema:DefinedTerm
120 Na08062b67012474eb9a5ac366e8eca21 rdf:first sg:person.01140136611.74
121 rdf:rest N19f65d7fbc8e477aacacdea9f7d387d4
122 Na54daa5cdbfb47bcb33a2559dafd3fd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Double-Blind Method
124 rdf:type schema:DefinedTerm
125 Naba7109830494de8bf1e2b347e1b729b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Patient Reported Outcome Measures
127 rdf:type schema:DefinedTerm
128 Nad33a0e3bfda4e75a8277f5b737a036a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Analgesics, Opioid
130 rdf:type schema:DefinedTerm
131 Nb1ce8de963ef430d93a9ff4e47cb7619 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Humans
133 rdf:type schema:DefinedTerm
134 Nb8dc420287a446d3b0a6d13fa0ba3cd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Quality of Life
136 rdf:type schema:DefinedTerm
137 Nc0e479021e884f87a28b86f4b669dfa4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Efficiency
139 rdf:type schema:DefinedTerm
140 Nc57718add948441e9a84465ba657e1eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Middle Aged
142 rdf:type schema:DefinedTerm
143 Nd168d2ac0bde4f888bf66275bff6d824 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Oxycodone
145 rdf:type schema:DefinedTerm
146 Nd95d07362b394bc3b91d0e2bddf67804 rdf:first sg:person.01230314714.19
147 rdf:rest N87319c496f4b40dbb486c32cbb38b0d9
148 Ndd46d161e47e4dc486248a6a46618095 rdf:first sg:person.01023710211.39
149 rdf:rest Na08062b67012474eb9a5ac366e8eca21
150 Nf13b1f8d16a142eea15dfad9fab7c807 schema:name nlm_unique_id
151 schema:value 101153626
152 rdf:type schema:PropertyValue
153 Nf7453204a42b461da2c907369244ed67 schema:name Springer Nature - SN SciGraph project
154 rdf:type schema:Organization
155 Nfcefb982c813478781a17869ae8c2f70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Female
157 rdf:type schema:DefinedTerm
158 Nfd1dcdef68c14313bf0bfb459bff78bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Drug Combinations
160 rdf:type schema:DefinedTerm
161 Nfe544422f6ec4bdab6696e7279784452 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Adult
163 rdf:type schema:DefinedTerm
164 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
165 schema:name Medical and Health Sciences
166 rdf:type schema:DefinedTerm
167 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
168 schema:name Public Health and Health Services
169 rdf:type schema:DefinedTerm
170 sg:journal.1031326 schema:issn 1477-7525
171 schema:name Health and Quality of Life Outcomes
172 rdf:type schema:Periodical
173 sg:person.01023710211.39 schema:affiliation N8cd634bc3bfb4137af1bd7869ac3ee92
174 schema:familyName Bass
175 schema:givenName Almasa
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023710211.39
177 rdf:type schema:Person
178 sg:person.01052152607.19 schema:affiliation N5b73de9a74554c7e89afa3332fd066c9
179 schema:familyName Wilson
180 schema:givenName Jacquelyn G.
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052152607.19
182 rdf:type schema:Person
183 sg:person.01105124405.55 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
184 schema:familyName Barsdorf
185 schema:givenName Alexandra I.
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105124405.55
187 rdf:type schema:Person
188 sg:person.01140136611.74 schema:affiliation N64c0302e2f1c4407b8bc38a6513371d2
189 schema:familyName Pixton
190 schema:givenName Glenn
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140136611.74
192 rdf:type schema:Person
193 sg:person.01210415200.45 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
194 schema:familyName Masters
195 schema:givenName Elizabeth T.
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210415200.45
197 rdf:type schema:Person
198 sg:person.01230314714.19 schema:affiliation https://www.grid.ac/institutes/grid.488790.a
199 schema:familyName Weil
200 schema:givenName Arnold J.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230314714.19
202 rdf:type schema:Person
203 sg:person.01342340211.86 schema:affiliation N4784861bc1c044f1b043f6bc53f1fb85
204 schema:familyName Wolfram
205 schema:givenName Gernot
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342340211.86
207 rdf:type schema:Person
208 sg:pub.10.1007/s11136-004-7713-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050041047
209 https://doi.org/10.1007/s11136-004-7713-0
210 rdf:type schema:CreativeWork
211 sg:pub.10.1007/s12325-014-0099-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046255156
212 https://doi.org/10.1007/s12325-014-0099-7
213 rdf:type schema:CreativeWork
214 sg:pub.10.2165/00019053-199304050-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027738237
215 https://doi.org/10.2165/00019053-199304050-00006
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1001/jama.2016.1464 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011046696
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1016/0168-8510(90)90421-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033898358
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1016/0168-8510(96)00822-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023757917
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/j.amjmed.2012.11.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028595156
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1016/j.jpain.2008.10.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017591588
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1016/j.jpain.2015.05.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015865413
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1016/j.pain.2012.03.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043275234
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1016/j.spinee.2007.11.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041594967
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1046/j.1524-4733.2003.65309.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041198010
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1097/ajp.0b013e3181b12dec schema:sameAs https://app.dimensions.ai/details/publication/pub.1020523539
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1097/j.pain.0000000000000230 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024509155
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1517/14656566.2010.491510 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037268596
240 rdf:type schema:CreativeWork
241 https://doi.org/10.15585/mmwr.mm655051e1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067984551
242 rdf:type schema:CreativeWork
243 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
244 schema:name Pfizer Inc, 235 E 42nd St, 10017, New York, NY, USA
245 rdf:type schema:Organization
246 https://www.grid.ac/institutes/grid.488790.a schema:alternateName Non-Surgical Orthopaedics (United States)
247 schema:name Non-Surgical Orthopaedics, PC, 335 Roselane St NW, 30067, Marietta, GA, USA
248 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...